2022 World Conference on Lung Cancer (ePosters)-EP08.02-065. Response to Systemic Anti-Cancer Therapy in Uncommon EGFR Mutations

EP08.02-065. Response to Systemic Anti-Cancer Therapy in Uncommon EGFR Mutations

Pdf Summary

This study aimed to evaluate the clinical outcomes of patients with rare EGFR mutations who received systemic anticancer therapy (SACT) at The Royal Marsden Lung Unit. Between January 2017 and September 2021, 23 patients with uncommon EGFR mutations were identified. Compound mutations were present in 23% of cases. EGFR kinase inhibitors (TKIs) were the most commonly prescribed first-line therapy, with an overall response rate of 47%. The median time to TKI discontinuation for compound mutations was 6 months, while for single mutations it was 4 months. Afatinib and osimertinib were the most frequently prescribed TKIs. <br /><br />In conclusion, EGFR TKIs have heterogeneous efficacy in patients with uncommon EGFR mutations. This study provides valuable data on the clinical outcomes of patients with rare EGFR mutations who received SACT. The findings highlight the importance of individualizing treatment approaches for patients with uncommon EGFR alterations, considering both single and compound mutations. Further research is needed to optimize treatment strategies for this patient population.

Asset Subtitle

Hazel M O'Sullivan

Meta Tag

Speaker Hazel M O'Sullivan

Topic Metastatic Non-small Cell Lung Cancer - Molecular Targeted Treatments

Keywords

clinical outcomes

patients

rare EGFR mutations

SACT

compound mutations

EGFR kinase inhibitors

overall response rate

TKI discontinuation

afatinib

osimertinib